Matthew Farren
Associate Director Incyte Corporation
Seminars
Tuesday 8th September 2026
Panel Discussion: How Do We Build Combination Strategies That Work Across KRAS Alleles, Co Mutations, & Tumor Types?
1:00 pm
- How do KRAS alleles, co‑mutations, and tumor lineage reshape dependency and escape, and what does that mean for choosing the right combination backbone?
- Which combinations have true cross‑context potential, and which are only effective in specific molecular or tumor‑type settings?
- How should we prioritise combinations that balance biological rationale, toxicity constraints, and real‑world feasibility across heterogeneous patient populations?
Tuesday 8th September 2026
Expanding Patient Reach: Developing Novel INCB161734 (KRAS G12D Inhibitors) Combinations That Work Across Heterogeneous Tumors
11:00 am
- Combining KRAS inhibitors with orthogonal agents in novel ways to increase the depth and breadth of efficacy in heterogenous tumors
- Reevaluating ways to broaden, not shrink, the treatable KRAS G12D patient population, avoiding combinations that only benefit narrow biomarker defined subsets
- Mutant-selective KRAS inhibitors enable maximal mutant KRAS inhibition while limiting off-tumor to the extent possible off-tumor activity
